EPHA4 Haploinsufficiency is Responsible for the Short Stature of a Patient with 2q35-q36.2 Deletion and Waardenburg Syndrome

Overview

Journal BMC Med Genet

Publisher Biomed Central

Specialty Genetics

Date 2015 May 1

PMID 25928000

Authors

Chuan Li

Rongyu Chen

Xin Fan

Jingsi Luo

JiaLe Qian

Jin Wang

Bobo Xie

Yiping Shen

Shaoke Chen

Affiliations

Soon will be listed here.

Abstract

Background: Waardenburg syndrome type I (WS1), an auditory-pigmentary genetic disorder, is caused by heterozygous loss-of-function mutations in PAX3. Abnormal physical signs such as dystopia canthorum, patchy hypopigmentation and sensorineural hearing loss are common, but short stature is not associated with WS1.

Case Presentation: We reported a 4-year and 6 month-old boy with a rare combination of WS1 and severe short stature (83.5 cm (-5.8SD)). His facial features include dystopia canthorum, mild synophrys, slightly up-slanted palpebral fissure, posteriorly rotated ears, alae nasi hypoplasia and micrognathia. No heterochromia was noticed. He had a normal intelligence quotient and hearing. Insulin-like growth factor-1 (IGF-1) was 52.7 ng/ml, lower than the normal range (55 ~ 452 ng/ml) and the peak growth hormone level was 7.57 ng/ml at 90 minutes after taking moderate levodopa and pyridostigmine bromide. The patient exhibited a good response to human growth hormone (rhGH) replacement therapy, showing a 9.2 cm/year growth rate and an improvement of 1 standard deviation (SD) of height after one year treatment. CMA test of patient's DNA revealed a 4.46 Mb de novo deletion at 2q35-q36.2 (hg19; chr2:221,234,146-225,697,363).

Conclusions: PAX3 haploinsufficiency is known to cause Waardenburg syndrome. Examining overlapping deletions in patients led to the conclusion that EPHA4 is a novel short stature gene. The finding is supported by the splotch-retarded and epha4 knockout mouse models which both showed growth retardation. We believe this rare condition is caused by the haploinsufficiency of both PAX3 and EPH4 genes. We further reported a growth response to recombinant human growth hormone treatment in this patient.

References

Warter S, LAUSECKER C, Pennerath A . [A girl with a deletion (2) (q34q36): cytogenetic and clinical observations (author's transl)]. Hum Genet. 1976; 32(2):225-7. DOI: 10.1007/BF00291510. View

Matsunaga T, Mutai H, Namba K, Morita N, Masuda S . Genetic analysis of PAX3 for diagnosis of Waardenburg syndrome type I. Acta Otolaryngol. 2012; 133(4):345-51. DOI: 10.3109/00016489.2012.744470. View

Epstein D, Malo D, Vekemans M, Gros P . Molecular characterization of a deletion encompassing the splotch mutation on mouse chromosome 1. Genomics. 1991; 10(1):89-93. DOI: 10.1016/0888-7543(91)90488-z. View

Farrer L, Grundfast K, Amos J, Arnos K, Asher Jr J, Beighton P . Waardenburg syndrome (WS) type I is caused by defects at multiple loci, one of which is near ALPP on chromosome 2: first report of the WS consortium. Am J Hum Genet. 1992; 50(5):902-13. PMC: 1682585. View

Melnyk A, Muraskas J . Interstitial deletion of chromosome 2 region in a malformed infant. Am J Med Genet. 1993; 45(1):49-51. DOI: 10.1002/ajmg.1320450114. View

Kirkpatrick S, Kent C, Laxova R, Sekhon G . Waardenburg syndrome type I in a child with deletion (2) (q35q36.2). Am J Med Genet. 1992; 44(5):699-700. DOI: 10.1002/ajmg.1320440533. View

Epstein D, Vogan K, TRASLER D, Gros P . A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci U S A. 1993; 90(2):532-6. PMC: 45697. DOI: 10.1073/pnas.90.2.532. View

Wu B, Milunsky A, Wyandt H, Hoth C, Baldwin C, Skare J . In situ hybridization applied to Waardenburg syndrome. Cytogenet Cell Genet. 1993; 63(1):29-32. DOI: 10.1159/000133495. View

Ward D, Spritz R . Fluorescence in situ hybridization mapping of 25 markers on distal human chromosome 2q surrounding the human Waardenburg syndrome, type I (WS1) locus (PAX3 gene). Genomics. 1993; 16(1):173-9. DOI: 10.1006/geno.1993.1155. View

10.

Pasteris N, Trask B, Sheldon S, Gorski J . Discordant phenotype of two overlapping deletions involving the PAX3 gene in chromosome 2q35. Hum Mol Genet. 1993; 2(7):953-9. DOI: 10.1093/hmg/2.7.953. View

11.

Vogan K, Epstein D, TRASLER D, Gros P . The splotch-delayed (Spd) mouse mutant carries a point mutation within the paired box of the Pax-3 gene. Genomics. 1993; 17(2):364-9. DOI: 10.1006/geno.1993.1333. View

12.

Tassabehji M, Newton V, Leverton K, Turnbull K, Seemanova E, Kunze J . PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse. Hum Mol Genet. 1994; 3(7):1069-74. DOI: 10.1093/hmg/3.7.1069. View

13.

Nye J, Balkin N, Lucas H, Knepper P, McLone D, Charrow J . Myelomeningocele and Waardenburg syndrome (type 3) in patients with interstitial deletions of 2q35 and the PAX3 gene: possible digenic inheritance of a neural tube defect. Am J Med Genet. 1998; 75(4):401-8. View

14.

Milunsky J, Maher T, Ito M, Milunsky A . The value of MLPA in Waardenburg syndrome. Genet Test. 2007; 11(2):179-82. DOI: 10.1089/gte.2006.0531. View

15.

Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N . Review and update of mutations causing Waardenburg syndrome. Hum Mutat. 2010; 31(4):391-406. DOI: 10.1002/humu.21211. View

16.

Jing X, Miyajima M, Sawada T, Chen Q, Iida K, Furushima K . Crosstalk of humoral and cell-cell contact-mediated signals in postnatal body growth. Cell Rep. 2012; 2(3):652-65. DOI: 10.1016/j.celrep.2012.08.021. View

17.

Arias S, Mota M . Apparent non-penetrance for dystopia in Waardenburg syndrome type I, with some hints on the diagnosis of dystopia canthorum. J Genet Hum. 1978; 26(2):103-31. View